Edition:
United Kingdom

3SBio Inc (1530.HK)

1530.HK on Hong Kong Stock

14.94HKD
23 Feb 2018
Change (% chg)

HK$-0.36 (-2.35%)
Prev Close
HK$15.30
Open
HK$15.78
Day's High
HK$15.78
Day's Low
HK$14.86
Volume
4,648,301
Avg. Vol
6,755,453
52-wk High
HK$17.90
52-wk Low
HK$7.58

Chart for

About

3SBio Inc. is an investment holding company, principally engaged in the development, production, marketing and sale of pharmaceutical products in Mainland China. The Company’s subsidiaries include Collected Mind Limited, Hongkong Sansheng Medical Limited and Shenyang Sunshine Pharmaceutical Co., Ltd.. Through its subsidiaries,... (more)

Overall

Beta: --
Market Cap(Mil.): HK$34,730.74
Shares Outstanding(Mil.): 2,538.80
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.60
EPS (TTM): -- -- --
ROI: -- 14.91 10.66
ROE: -- 16.41 14.30

BRIEF-3SBio Announces Tpiao Injection gets Approval For Clinical Trials For Additional Indication By CFDA

* TPIAO INJECTION GRANTED APPROVAL FOR CLINICAL TRIALS FOR ADDITIONAL INDICATION BY CHINA FOOD AND DRUG ADMINISTRATION​ Source text for Eikon: Further company coverage:

22 Feb 2018

BRIEF-3Sbio Says Unit And Toray Sign Exclusive Licensing Agreement On Antipuritic Agent, TRK-820​

* UNIT AND TORAY ENTER EXCLUSIVE LICENSING AGREEMENT ON CERTAIN ORAL DISINTEGRATION TABLET FORMULATION OF ANTIPRURITIC DRUG TRK-820​ Source text for Eikon: Further company coverage:

15 Jan 2018

BRIEF-3SBio Says ‍China FDA Approves New Once-Weekly Bydureon To Improve Glycemic Control​

* ‍CHINA FDA APPROVES NEW ONCE-WEEKLY BYDUREON TO IMPROVE GLYCEMIC CONTROL​ Source text for Eikon: Further company coverage:

04 Jan 2018

BRIEF-3SBio Inc says 601a approved by China FDA for clinical trials ​

* Recombinant humanized anti-VEGF monoclonal antibody for injection (601a) approved by China FDA for clinical trials ​ Source text for Eikon: Further company coverage:

11 Oct 2017

Chinese biopharma 3SBio in $290 million deal for unit of Canada's Therapure

SHANGHAI China's 3SBio Inc has agreed to buy the contract development and manufacturing unit of Canada's Therapure Biopharma Inc for $290 million, part of a push by the Chinese biotech company into the North American market.

04 Sep 2017

Chinese biopharma 3SBio in $290 mln deal for unit of Canada's Therapure

SHANGHAI, Sept 4 China's 3SBio Inc has agreed to buy the contract development and manufacturing unit of Canada's Therapure Biopharma Inc for $290 million, part of a push by the Chinese biotech company into the North American market.

04 Sep 2017

Earnings vs. Estimates